TY - JOUR AU - Kadam, Sonal AU - Sri Boppana, Swapna AU - Manna, Sukanta AU - Datta, Suman AU - Karande, Sunil PY - 2022/04/09 Y2 - 2024/03/29 TI - Management of hypertension: Comparison of Telmisartan with other antihypertensive drugs JF - Medico Research Chronicles JA - Med. res. chronicles VL - 9 IS - 2 SE - Original Research Article DO - 10.26838/MEDRECH.2022.9.2.584 UR - https://medrech.com/index.php/medrech/article/view/567 SP - 88-93 AB - Angiotensin II type 1 receptor antagonists (ARBs) are highly effective antihypertensive drugs used clinically for the management of hypertension, prevention of heart failure, and protecting diabetic nephropathy. Hypertension is the most prevalent lifestyle disease affecting the cardiovascular system and a major risk factor for stroke. The ARBs are very effective in decreasing elevated blood pressure (BP) to a normal level. Additionally, they do not have side effects like cough and angioedema, as shown by other classes of antihypertensive drugs like angiotensin-converting enzyme inhibitors. This feature makes ARBs the most preferred therapeutic strategy for hypertension. Telmisartan is an ARB, approved by the Food and Drug Administration for the treatment of hypertension in 1998, and is proven to provide efficient and lasting BP control when compared to other agents. This review highlights several clinical trials carried out to compare the efficacy, safety, and tolerability of telmisartan with other antihypertensive agents. ER -